Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial

  1. Flygt, Hjalmar ORCID logo
  2. Söderlund, Stina
  3. Richter, Johan ORCID logo
  4. Saußele, Susanne ORCID logo
  5. Koskenvesa, Perttu
  6. Stenke, Leif
  7. Mustjoki, Satu ORCID logo
  8. Dimitrijevic, Andreja ORCID logo
  9. Stentoft, Jesper
  10. Majeed, Waleed
  11. Roy, Lydia
  12. Wolf, Dominik
  13. Dreimane, Arta
  14. Gjertsen, Bjørn Tore
  15. Gedde-Dahl, Tobias
  16. Ahlstrand, Erik
  17. Markevärn, Berit
  18. Hjorth-Hansen, Henrik
  19. Janssen, Jeroen
  20. Olsson-Strömberg, Ulla

Download
41375_2024_Article_2145.pdf 1,04MB
WeightNameValue
1000 Titel
  • Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial
1000 Autor/in
  1. Flygt, Hjalmar |
  2. Söderlund, Stina |
  3. Richter, Johan |
  4. Saußele, Susanne |
  5. Koskenvesa, Perttu |
  6. Stenke, Leif |
  7. Mustjoki, Satu |
  8. Dimitrijevic, Andreja |
  9. Stentoft, Jesper |
  10. Majeed, Waleed |
  11. Roy, Lydia |
  12. Wolf, Dominik |
  13. Dreimane, Arta |
  14. Gjertsen, Bjørn Tore |
  15. Gedde-Dahl, Tobias |
  16. Ahlstrand, Erik |
  17. Markevärn, Berit |
  18. Hjorth-Hansen, Henrik |
  19. Janssen, Jeroen |
  20. Olsson-Strömberg, Ulla |
1000 Verlag Nature Publishing Group UK
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-01-26
1000 Erschienen in
1000 Quellenangabe
  • 38(4):781-787
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41375-024-02145-6 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10997495/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular relapse upon TKI cessation. Most of them quickly regain DMR upon TKI resumption. Whether these patients can achieve a second treatment-free remission (TFR) remains unclear. DAstop2 (ClinicalTrials.gov ID: NCT03573596) is a prospective study including patients with a failed first TFR attempt re-treated with any TKI for ≥ one year. Upon entering the study, patients received the TKI dasatinib for additional two years. Patients with sustained DMR for ≥1 year qualified for a second TKI stop. Ninety-four patients were included between Oct 2017-Dec 2021. At the time of data analysis, 62 patients had attempted a 2<jats:sup>nd</jats:sup> stop. After a median follow-up of 27 months from 2<jats:sup>nd</jats:sup> stop, TFR rates were 61, 56 and 46% at 6, 12 and 24 months respectively. No progression to advanced stage disease was seen and 87% had re-achieved MR<jats:sup>4</jats:sup> within a median of 3 months from TKI re-initiation. In summary, we show that a 2<jats:sup>nd</jats:sup> TFR attempt after dasatinib treatment is safe, feasible and TFR rates seem in the range of those reported in trials of a first TKI stop.</jats:p>
1000 Sacherschließung
lokal Dasatinib/adverse effects [MeSH]
lokal Article
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal Treatment Outcome [MeSH]
lokal Remission Induction [MeSH]
lokal /631/67/1990/2331
lokal /631/67/1059/602
lokal Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy [MeSH]
lokal article
lokal Protein Kinase Inhibitors/adverse effects [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-8912-2324|https://frl.publisso.de/adhoc/uri/U8O2ZGVybHVuZCwgU3RpbmE=|https://orcid.org/0000-0002-0374-6823|https://orcid.org/0000-0003-0357-5785|https://frl.publisso.de/adhoc/uri/S29za2VudmVzYSwgUGVydHR1|https://frl.publisso.de/adhoc/uri/U3RlbmtlLCBMZWlm|https://orcid.org/0000-0002-0816-8241|https://orcid.org/0000-0002-0125-1886|https://frl.publisso.de/adhoc/uri/U3RlbnRvZnQsIEplc3Blcg==|https://frl.publisso.de/adhoc/uri/TWFqZWVkLCBXYWxlZWQ=|https://frl.publisso.de/adhoc/uri/Um95LCBMeWRpYQ==|https://frl.publisso.de/adhoc/uri/V29sZiwgRG9taW5paw==|https://frl.publisso.de/adhoc/uri/RHJlaW1hbmUsIEFydGE=|https://frl.publisso.de/adhoc/uri/R2plcnRzZW4sIEJqw7hybiBUb3Jl|https://frl.publisso.de/adhoc/uri/R2VkZGUtRGFobCwgVG9iaWFz|https://frl.publisso.de/adhoc/uri/QWhsc3RyYW5kLCBFcmlr|https://frl.publisso.de/adhoc/uri/TWFya2V2w6RybiwgQmVyaXQ=|https://frl.publisso.de/adhoc/uri/SGpvcnRoLUhhbnNlbiwgSGVucmlr|https://frl.publisso.de/adhoc/uri/SmFuc3NlbiwgSmVyb2Vu|https://frl.publisso.de/adhoc/uri/T2xzc29uLVN0csO2bWJlcmcsIFVsbGE=
1000 Hinweis
  • DeepGreen-ID: d56d21922b2243cdad06b51a31a38583 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6519387.rdf
1000 Erstellt am 2025-07-05T17:34:16.898+0200
1000 Erstellt von 322
1000 beschreibt frl:6519387
1000 Zuletzt bearbeitet 2025-08-14T08:11:18.904+0200
1000 Objekt bearb. Thu Aug 14 08:11:18 CEST 2025
1000 Vgl. frl:6519387
1000 Oai Id
  1. oai:frl.publisso.de:frl:6519387 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source